Vasculopathy in the setting of cardiorenal syndrome: Roles of protein-bound uremic toxins

Jingbin Guo, Lu Lu, Yue Hua, Kevin Huang, Ian Wang, Li Huang, Qiang Fu, Aihua Chen, Paul Chan, Huimin Fan, Zhong Min Liu, Bing Hui Wang

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) often leads to and accelerates the progression of cardiovascular disease (CVD), while CVD also causes kidney dysfunction. This bidirectional interaction leads to the development of a complex syndrome known as cardiorenal syndrome (CRS). CRS not only involves both the heart and the kidney but also the vascular system through a vast array of contributing factors. In addition to hemodynamic, neurohormonal, mechanical, and biochemical factors, nondialyzable protein-bound uremic toxins (PBUTs) are also key contributing factors that have been demonstrated through in vitro, in vivo, and clinical observations. PBUTs are ineffectively removed by hemodialysis because their complexes with albumins are larger than the pores of the dialysis membranes. PBUTs such as indoxyl sulfate and p-cresyl sulfate are key determinate and predictive factors for the progression of CVD in CKD patients. In CRS, both vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) exhibit significant dysfunction that is associated with the progression of CVD. PBUTs influence proliferation, calcification, senescence, migration, inflammation, and oxidative stress in VSMCs and ECs through various mechanisms. These pathological changes lead to arterial remodeling, stiffness, and atherosclerosis and thus reduce heart perfusion and impair left ventricular function, aggravating CRS. There is limited literature about the effect of PBUT on the vascular system and their contribution to CRS. This review summarizes current knowledge on how PBUTs influence vasculature, clarifies the relationship between uremic toxin-related vascular disease and CRS, and highlights the potential therapeutic strategies of uremic vasculopathy in the setting of CRS.

Original languageEnglish
Pages (from-to)H1-H13
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume313
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Cardio-Renal Syndrome
Cardiovascular Diseases
Proteins
Chronic Renal Insufficiency
Vascular Smooth Muscle
Smooth Muscle Myocytes
Blood Vessels
Indican
Endothelial Cells
Kidney
Vascular Stiffness
Vascular Diseases
Left Ventricular Function
Sulfates
Renal Dialysis
Dialysis
Albumins
Atherosclerosis
Oxidative Stress
Perfusion

Keywords

  • Cardiorenal syndrome
  • Endothelial cells
  • Protein-bound uremic toxins
  • Vascular smooth muscle cells
  • Vasculopathy

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Vasculopathy in the setting of cardiorenal syndrome : Roles of protein-bound uremic toxins. / Guo, Jingbin; Lu, Lu; Hua, Yue; Huang, Kevin; Wang, Ian; Huang, Li; Fu, Qiang; Chen, Aihua; Chan, Paul; Fan, Huimin; Liu, Zhong Min; Wang, Bing Hui.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 313, No. 1, 2017, p. H1-H13.

Research output: Contribution to journalReview article

Guo, Jingbin ; Lu, Lu ; Hua, Yue ; Huang, Kevin ; Wang, Ian ; Huang, Li ; Fu, Qiang ; Chen, Aihua ; Chan, Paul ; Fan, Huimin ; Liu, Zhong Min ; Wang, Bing Hui. / Vasculopathy in the setting of cardiorenal syndrome : Roles of protein-bound uremic toxins. In: American Journal of Physiology - Heart and Circulatory Physiology. 2017 ; Vol. 313, No. 1. pp. H1-H13.
@article{d867b1220ba54e9eac8da3dbe2697921,
title = "Vasculopathy in the setting of cardiorenal syndrome: Roles of protein-bound uremic toxins",
abstract = "Chronic kidney disease (CKD) often leads to and accelerates the progression of cardiovascular disease (CVD), while CVD also causes kidney dysfunction. This bidirectional interaction leads to the development of a complex syndrome known as cardiorenal syndrome (CRS). CRS not only involves both the heart and the kidney but also the vascular system through a vast array of contributing factors. In addition to hemodynamic, neurohormonal, mechanical, and biochemical factors, nondialyzable protein-bound uremic toxins (PBUTs) are also key contributing factors that have been demonstrated through in vitro, in vivo, and clinical observations. PBUTs are ineffectively removed by hemodialysis because their complexes with albumins are larger than the pores of the dialysis membranes. PBUTs such as indoxyl sulfate and p-cresyl sulfate are key determinate and predictive factors for the progression of CVD in CKD patients. In CRS, both vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) exhibit significant dysfunction that is associated with the progression of CVD. PBUTs influence proliferation, calcification, senescence, migration, inflammation, and oxidative stress in VSMCs and ECs through various mechanisms. These pathological changes lead to arterial remodeling, stiffness, and atherosclerosis and thus reduce heart perfusion and impair left ventricular function, aggravating CRS. There is limited literature about the effect of PBUT on the vascular system and their contribution to CRS. This review summarizes current knowledge on how PBUTs influence vasculature, clarifies the relationship between uremic toxin-related vascular disease and CRS, and highlights the potential therapeutic strategies of uremic vasculopathy in the setting of CRS.",
keywords = "Cardiorenal syndrome, Endothelial cells, Protein-bound uremic toxins, Vascular smooth muscle cells, Vasculopathy",
author = "Jingbin Guo and Lu Lu and Yue Hua and Kevin Huang and Ian Wang and Li Huang and Qiang Fu and Aihua Chen and Paul Chan and Huimin Fan and Liu, {Zhong Min} and Wang, {Bing Hui}",
year = "2017",
doi = "10.1152/ajpheart.00787.2016",
language = "English",
volume = "313",
pages = "H1--H13",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Vasculopathy in the setting of cardiorenal syndrome

T2 - Roles of protein-bound uremic toxins

AU - Guo, Jingbin

AU - Lu, Lu

AU - Hua, Yue

AU - Huang, Kevin

AU - Wang, Ian

AU - Huang, Li

AU - Fu, Qiang

AU - Chen, Aihua

AU - Chan, Paul

AU - Fan, Huimin

AU - Liu, Zhong Min

AU - Wang, Bing Hui

PY - 2017

Y1 - 2017

N2 - Chronic kidney disease (CKD) often leads to and accelerates the progression of cardiovascular disease (CVD), while CVD also causes kidney dysfunction. This bidirectional interaction leads to the development of a complex syndrome known as cardiorenal syndrome (CRS). CRS not only involves both the heart and the kidney but also the vascular system through a vast array of contributing factors. In addition to hemodynamic, neurohormonal, mechanical, and biochemical factors, nondialyzable protein-bound uremic toxins (PBUTs) are also key contributing factors that have been demonstrated through in vitro, in vivo, and clinical observations. PBUTs are ineffectively removed by hemodialysis because their complexes with albumins are larger than the pores of the dialysis membranes. PBUTs such as indoxyl sulfate and p-cresyl sulfate are key determinate and predictive factors for the progression of CVD in CKD patients. In CRS, both vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) exhibit significant dysfunction that is associated with the progression of CVD. PBUTs influence proliferation, calcification, senescence, migration, inflammation, and oxidative stress in VSMCs and ECs through various mechanisms. These pathological changes lead to arterial remodeling, stiffness, and atherosclerosis and thus reduce heart perfusion and impair left ventricular function, aggravating CRS. There is limited literature about the effect of PBUT on the vascular system and their contribution to CRS. This review summarizes current knowledge on how PBUTs influence vasculature, clarifies the relationship between uremic toxin-related vascular disease and CRS, and highlights the potential therapeutic strategies of uremic vasculopathy in the setting of CRS.

AB - Chronic kidney disease (CKD) often leads to and accelerates the progression of cardiovascular disease (CVD), while CVD also causes kidney dysfunction. This bidirectional interaction leads to the development of a complex syndrome known as cardiorenal syndrome (CRS). CRS not only involves both the heart and the kidney but also the vascular system through a vast array of contributing factors. In addition to hemodynamic, neurohormonal, mechanical, and biochemical factors, nondialyzable protein-bound uremic toxins (PBUTs) are also key contributing factors that have been demonstrated through in vitro, in vivo, and clinical observations. PBUTs are ineffectively removed by hemodialysis because their complexes with albumins are larger than the pores of the dialysis membranes. PBUTs such as indoxyl sulfate and p-cresyl sulfate are key determinate and predictive factors for the progression of CVD in CKD patients. In CRS, both vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) exhibit significant dysfunction that is associated with the progression of CVD. PBUTs influence proliferation, calcification, senescence, migration, inflammation, and oxidative stress in VSMCs and ECs through various mechanisms. These pathological changes lead to arterial remodeling, stiffness, and atherosclerosis and thus reduce heart perfusion and impair left ventricular function, aggravating CRS. There is limited literature about the effect of PBUT on the vascular system and their contribution to CRS. This review summarizes current knowledge on how PBUTs influence vasculature, clarifies the relationship between uremic toxin-related vascular disease and CRS, and highlights the potential therapeutic strategies of uremic vasculopathy in the setting of CRS.

KW - Cardiorenal syndrome

KW - Endothelial cells

KW - Protein-bound uremic toxins

KW - Vascular smooth muscle cells

KW - Vasculopathy

UR - http://www.scopus.com/inward/record.url?scp=85021818978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021818978&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00787.2016

DO - 10.1152/ajpheart.00787.2016

M3 - Review article

C2 - 28411233

AN - SCOPUS:85021818978

VL - 313

SP - H1-H13

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 1

ER -